Yıl: 2022 Cilt: 33 Sayı: 2 Sayfa Aralığı: 440 - 448 Metin Dili: İngilizce DOI: 10.52312/jdrs.2022.526 İndeks Tarihi: 21-09-2022

Evaluation of prognostic factors affecting survival in chondrosarcoma treatment and comparison with literature

Öz:
Objectives: The aim of this study was to identify the demographic characteristics of chondrosarcoma (CS) and prognostic factors affecting survival. Patients and methods: A total of 87 patients (45 males, 42 females; median age: 51.3 years; range, 19 to 77 years) with CS treated in our clinic between January 2007 and June 2020 were retrospectively analyzed. Demographic characteristics, whether it was primary/secondary, tumor location, histopathological features, tumor grade and stage, clinical follow-up period, surgical treatment methods, use of radiotherapy and chemotherapy, and the presence of local recurrence and metastasis in the postoperative period were recorded. The relationship of these factors with prognosis was analyzed and survival rates were compared. Results: Histological subtype, tumor grade, pathological stage and presence of metastasis were defined as independent predictors in both overall survival and disease-free survival analysis of CS. Overall and disease-free five-year and 10-year survival rates were found to be the highest in the clear cell chondrosarcoma group. While mortality increased in the first five years in the patient groups with histological Grade 2 and 3, all groups were followed in a balanced manner over time. The mortality rate in the group with metastatic disease (M2) was approximately four times higher than the other groups at 10-year follow-up. According to the surgical margins, we found that the five-year survival rates of the R1 (marginal resection) and R2 (residual tumor) groups were similar, with the highest rate being in the R0 (wide resection) group with 78.3%. In multivariate analysis, only grade and stage had a significant association with disease-specific survival. Surgical resection combined with adjuvant radiotherapy was found to increase survival in both overall and disease-free survival of patients with dedifferentiated chondrosarcoma compared to other treatments. Conclusion: Histological subtype, grade, stage and presence of metastasis were the independent prognostic factors for survival in CS. However, marginal resection was a risk factor for local recurrence (LR), but there was no significant difference in overall survival in patients with or without LR. Although it is not significant, radiotherapy could increase survival in dedifferentiated CS variants.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R, Scully SP. Chondrosarcoma in the United States (1973 to 2003): An analysis of 2890 cases from the SEER database. J Bone Joint Surg [Am] 2009;91:1063-72.
  • 2. Sundaresan N, Rosen G, Boriani S. Primary malignant tumors of the spine. Orthop Clin North Am 2009;40:21-36.
  • 3. Gao Z, Lu T, Song H, Gao Z, Ren F, Ouyang P, et al. Prognostic factors and treatment options for patients with high-grade chondrosarcoma. Med Sci Monit 2019;25:8952-67.
  • 4. Fiorenza F, Abudu A, Grimer RJ, Carter SR, Tillman RM, Ayoub K, et al. Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg [Br] 2002;84:93-9.
  • 5. MacDonald IJ, Lin CY, Kuo SJ, Su CM, Tang CH. An update on current and future treatment options for chondrosarcoma. Expert Rev Anticancer Ther 2019;19:773-86.
  • 6. Tanaka K, Ozaki T. New TNM classification (AJCC eighth edition) of bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. Jpn J Clin Oncol 2019;49:103-7.
  • 7. Fleming ID. AJCC/TNM cancer staging, present and future. J Surg Oncol 2001;77:233-6.
  • 8. Biermann JS, Chow W, Reed DR, Lucas D, Adkins DR, Agulnik M, et al. NCCN guidelines insights: Bone cancer, Version 2.2017. J Natl Compr Canc Netw 2017;15:155-67.
  • 9. Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res 2007;459:40-7.
  • 10. Lin PP, Moussallem CD, Deavers MT. Secondary chondrosarcoma. J Am Acad Orthop Surg 2010;18:608-15.
  • 11. Amer KM, Munn M, Congiusta D, Abraham JA, Basu Mallick A. Survival and prognosis of chondrosarcoma subtypes: SEER Database Analysis. J Orthop Res 2020;38:311-9.
  • 12. Nota SP, Braun Y, Schwab JH, van Dijk CN, Bramer JA. The identification of prognostic factors and survival statistics of conventional central chondrosarcoma. Sarcoma 2015;2015:623746.
  • 13. Ahmed AR, Tan TS, Unni KK, Collins MS, Wenger DE, Sim FH. Secondary chondrosarcoma in osteochondroma: report of 107 patients. Clin Orthop Relat Res 2003;411:193-206.
  • 14. Tsuda Y, Gregory JJ, Fujiwara T, Abudu S. Secondary chondrosarcoma arising from osteochondroma: Outcomes and prognostic factors. Bone Joint J 2019;101-B:1313-20.
  • 15. Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH, et al. The clinical approach towards chondrosarcoma. Oncologist 2008;13:320-9.
  • 16. Fromm J, Klein A, Baur-Melnyk A, Knösel T, Lindner L, Birkenmaier C, et al. Survival and prognostic factors in conventional G1 chondrosarcoma. World J Surg Oncol 2019;17:155.
  • 17. Andreou D, Ruppin S, Fehlberg S, Pink D, Werner M, Tunn PU. Survival and prognostic factors in chondrosarcoma: Results in 115 patients with long-term follow-up. Acta Orthop 2011;82:749-55.
  • 18. Huang R, Sun Z, Zheng H, Yan P, Hu P, Yin H, et al. Identifying the prognosis factors and predicting the survival probability in patients with non-metastatic chondrosarcoma from the SEER database. Orthop Surg 2019;11:801-10.
  • 19. Angelini A, Guerra G, Mavrogenis AF, Pala E, Picci P, Ruggieri P. Clinical outcome of central conventional chondrosarcoma. J Surg Oncol 2012;106:929-37.
  • 20. Laitinen MK, Parry MC, Le Nail LR, Wigley CH, Stevenson JD, Jeys LM. Locally recurrent chondrosarcoma of the pelvis and limbs can only be controlled by wide local excision. Bone Joint J 2019;101-B:266-71.
  • 21. Söderström M, Ekfors TO, Böhling TO, Teppo LH, Vuorio EI, Aro HT. No improvement in the overall survival of 194 patients with chondrosarcoma in Finland in 1971-1990. Acta Orthop Scand 2003;74:344-50.
  • 22. Krochak R, Harwood AR, Cummings BJ, Quirt IC. Results of radical radiation for chondrosarcoma of bone. Radiother Oncol 1983;1:109-15.
  • 23. Italiano A, Mir O, Cioffi A, Palmerini E, Piperno-Neumann S, Perrin C, et al. Advanced chondrosarcomas: Role of chemotherapy and survival. Ann Oncol 2013;24:2916-22.
  • 24. Cesari M, Bertoni F, Bacchini P, Mercuri M, Palmerini E, Ferrari S. Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. Tumori 2007;93:423-7.
  • 25. Frezza AM, Cesari M, Baumhoer D, Biau D, Bielack S, Campanacci DA, et al. Mesenchymal chondrosarcoma: Prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. Eur J Cancer 2015;51:374-81.
  • 26. Mirra JM, Gold R, Downs J, Eckardt JJ. A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases. Clin Orthop Relat Res 1985;201:214-37.
  • 27. Mankin HJ, Cantley KP, Lippiello L, Schiller AL, Campbell CJ. The biology of human chondrosarcoma. I. Description of the cases, grading, and biochemical analyses. J Bone Joint Surg Am 1980;62:160-76.
  • 28. Mosier SM, Patel T, Strenge K, Mosier AD. Chondrosarcoma in childhood: The radiologic and clinical conundrum. J Radiol Case Rep 2012;6:32-42.
  • 29. Afonso PD, Isaac A, Villagrán JM. Chondroid tumors as incidental findings and differential diagnosis between enchondromas and low-grade chondrosarcomas. Semin Musculoskelet Radiol 2019;23:3-18.
  • 30. Yapar A, Ulucaköy C, Sezgin EA, Atalay İB, Ekşioğlu MF. Diagnostic role of neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio in patients with enchondroma and low-grade chondrosarcoma. Jt Dis Relat Surg 2020;31:286-90.
APA COSKUN H, ERDOĞAN F, büyükceran i, Dabak N (2022). Evaluation of prognostic factors affecting survival in chondrosarcoma treatment and comparison with literature. , 440 - 448. 10.52312/jdrs.2022.526
Chicago COSKUN Huseyin Sina,ERDOĞAN Furkan,büyükceran ismail,Dabak Nevzat Evaluation of prognostic factors affecting survival in chondrosarcoma treatment and comparison with literature. (2022): 440 - 448. 10.52312/jdrs.2022.526
MLA COSKUN Huseyin Sina,ERDOĞAN Furkan,büyükceran ismail,Dabak Nevzat Evaluation of prognostic factors affecting survival in chondrosarcoma treatment and comparison with literature. , 2022, ss.440 - 448. 10.52312/jdrs.2022.526
AMA COSKUN H,ERDOĞAN F,büyükceran i,Dabak N Evaluation of prognostic factors affecting survival in chondrosarcoma treatment and comparison with literature. . 2022; 440 - 448. 10.52312/jdrs.2022.526
Vancouver COSKUN H,ERDOĞAN F,büyükceran i,Dabak N Evaluation of prognostic factors affecting survival in chondrosarcoma treatment and comparison with literature. . 2022; 440 - 448. 10.52312/jdrs.2022.526
IEEE COSKUN H,ERDOĞAN F,büyükceran i,Dabak N "Evaluation of prognostic factors affecting survival in chondrosarcoma treatment and comparison with literature." , ss.440 - 448, 2022. 10.52312/jdrs.2022.526
ISNAD COSKUN, Huseyin Sina vd. "Evaluation of prognostic factors affecting survival in chondrosarcoma treatment and comparison with literature". (2022), 440-448. https://doi.org/10.52312/jdrs.2022.526
APA COSKUN H, ERDOĞAN F, büyükceran i, Dabak N (2022). Evaluation of prognostic factors affecting survival in chondrosarcoma treatment and comparison with literature. Joint diseases and related surgery, 33(2), 440 - 448. 10.52312/jdrs.2022.526
Chicago COSKUN Huseyin Sina,ERDOĞAN Furkan,büyükceran ismail,Dabak Nevzat Evaluation of prognostic factors affecting survival in chondrosarcoma treatment and comparison with literature. Joint diseases and related surgery 33, no.2 (2022): 440 - 448. 10.52312/jdrs.2022.526
MLA COSKUN Huseyin Sina,ERDOĞAN Furkan,büyükceran ismail,Dabak Nevzat Evaluation of prognostic factors affecting survival in chondrosarcoma treatment and comparison with literature. Joint diseases and related surgery, vol.33, no.2, 2022, ss.440 - 448. 10.52312/jdrs.2022.526
AMA COSKUN H,ERDOĞAN F,büyükceran i,Dabak N Evaluation of prognostic factors affecting survival in chondrosarcoma treatment and comparison with literature. Joint diseases and related surgery. 2022; 33(2): 440 - 448. 10.52312/jdrs.2022.526
Vancouver COSKUN H,ERDOĞAN F,büyükceran i,Dabak N Evaluation of prognostic factors affecting survival in chondrosarcoma treatment and comparison with literature. Joint diseases and related surgery. 2022; 33(2): 440 - 448. 10.52312/jdrs.2022.526
IEEE COSKUN H,ERDOĞAN F,büyükceran i,Dabak N "Evaluation of prognostic factors affecting survival in chondrosarcoma treatment and comparison with literature." Joint diseases and related surgery, 33, ss.440 - 448, 2022. 10.52312/jdrs.2022.526
ISNAD COSKUN, Huseyin Sina vd. "Evaluation of prognostic factors affecting survival in chondrosarcoma treatment and comparison with literature". Joint diseases and related surgery 33/2 (2022), 440-448. https://doi.org/10.52312/jdrs.2022.526